Journal Publications

Alawy M, Tawfick W, ElKassaby M, Shalaby A, Zaki M, Hynes N, Sultan S. Late dacron patch inflammatory reaction after carotid endarterectomy. European Journal of Vascular and Endovascular Surgery. 2017 Jul 27.

Sultan S, Kavanagh EP, Hynes N. Current Status of Vascular Training Schemes in Europe: Recommendations for a New Global Teaching Curriculum. InVascular Surgery 2017 (pp. 357-363). Springer International Publishing.

Wise Jacqui, . Long term study backs statins for patients with high LDL and no other risk factors BMJ  2017;  358 :j4171

Sultan S, Kavanagh EP, Michalus R, Hynes N. Stem Cell Smart Technology, where are we now and how far we have to go?. Vascular. 2017 Jan 1:1708538117727429.

Sultan S, Kavanagh EP, Diethrich E, Costache V, Sultan M, Jordan F, Hynes N. A clinical review of early outcomes from contemporary flow modulation versus open, fenestrated and branch technologies in the management of thoracoabdominal aortic aneurysm. Vascular. 2017 Jan 1:1708538117724933.

Sultan S, Kavanagh EP, Tawfick W, Hynes N. Endovascular Repair of rAAA (rEVAR) versus Open Repair (OR), a Contemporary Comparison of the Paradigm Shift in Rupture AAA Management: Leading Vascular Surgery Expert Sherif Sultan, MD.

Sultan S, Kavanagh EP, Stefanov F, Sultan M, Elhelali A, Costache V, Diethrich E, Hynes N, Collaborators GM. Endovascular management of chronic symptomatic aortic dissection with the Streamliner Multilayer Flow Modulator: Twelve-month outcomes from the global registry. Journal of Vascular Surgery. 2017 Apr 30;65(4):940-50.

Stefanov F, Sultan S, Morris L, Elhelali A, Kavanagh EP, Lundon V, Sultan M, Hynes N. Computational fluid analysis of symptomatic chronic type B aortic dissections managed with the Streamliner Multilayer Flow Modulator. Journal of Vascular Surgery. 2017 Apr 30;65(4):951-63.

Sultan S, Kavanagh EP, Costache V, Sultan M, Stefanov F, Sultan M, Elhelali A,  Diethrich E, Jordan F, Hynes N. Streamliner Multilayer Flow Modulator for Thoracoabdominal Aortic Pathologies: Recommendations for Revision of Indications and Contraindications for Use. VASCULAR DISEASE MANAGEMENT 2017;14(4):E90-E99.